Fate Therapeutics, Inc. (FATE)
2.34
-0.09
(-3.70%)
USD |
NASDAQ |
Sep 24, 16:00
2.34
0.00 (0.00%)
After-Hours: 17:10
Fate Therapeutics Price to Book Value : 1.780 for Sept. 24, 2026
Price to Book Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Price to Book Value Data
| Date | Value |
|---|---|
| September 23, 2026 | 1.848 |
| September 22, 2026 | 1.962 |
| September 21, 2026 | 1.924 |
| September 18, 2026 | 1.924 |
| September 17, 2026 | 1.917 |
| September 16, 2026 | 1.856 |
| September 15, 2026 | 1.787 |
| September 14, 2026 | 1.780 |
| September 11, 2026 | 1.757 |
| September 10, 2026 | 1.772 |
| September 09, 2026 | 1.856 |
| September 08, 2026 | 1.901 |
| September 04, 2026 | 1.886 |
| September 03, 2026 | 1.840 |
| September 02, 2026 | 1.863 |
| September 01, 2026 | 1.848 |
| August 31, 2026 | 1.818 |
| August 28, 2026 | 1.848 |
| August 27, 2026 | 1.932 |
| August 26, 2026 | 1.955 |
| August 25, 2026 | 1.939 |
| August 24, 2026 | 1.856 |
| August 21, 2026 | 1.772 |
| August 20, 2026 | 1.863 |
| August 19, 2026 | 2.015 |
| Date | Value |
|---|---|
| August 18, 2026 | 1.947 |
| August 17, 2026 | 1.993 |
| August 14, 2026 | 1.955 |
| August 13, 2026 | 1.917 |
| August 12, 2026 | 2.069 |
| August 11, 2026 | 2.084 |
| August 10, 2026 | 2.099 |
| August 07, 2026 | 2.130 |
| August 06, 2026 | 1.894 |
| August 05, 2026 | 1.977 |
| August 04, 2026 | 1.955 |
| August 03, 2026 | 1.901 |
| July 31, 2026 | 1.863 |
| July 30, 2026 | 1.909 |
| July 29, 2026 | 1.795 |
| July 28, 2026 | 1.764 |
| July 27, 2026 | 1.848 |
| July 24, 2026 | 1.833 |
| July 23, 2026 | 1.917 |
| July 22, 2026 | 1.962 |
| July 21, 2026 | 2.152 |
| July 20, 2026 | 2.126 |
| July 17, 2026 | 2.114 |
| July 16, 2026 | 2.076 |
| July 15, 2026 | 2.274 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Agenus, Inc. | -- |
| Amgen, Inc. | 18.78 |
| Anika Therapeutics, Inc. | 1.977 |
| BioCryst Pharmaceuticals, Inc. | -- |
| Imunon, Inc. | 1.481 |
Price to Book Value Related Metrics
| PS Ratio | 43.14 |
| Price | 2.34 |
| Earnings Yield | -45.00% |
| Market Cap | 273.06M |